CD24Fc (MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)
Status:
Completed
Trial end date:
2020-10-20
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy and safety of CD24Fc (MK-7110) in hospitalized adult
participants who are diagnosed with coronavirus disease 2019 (COVID-19) and receiving oxygen
support.
The primary hypothesis of the study is clinical improvement in the experimental group versus
the control group.